Antibiotic Efficacy Testing in an Ex vivo Model of <em>Pseudomonas aeruginosa</em> and <em>Staphylococcus aureus</em> Biofilms in the Cystic Fibrosis Lung

Niamh E. Harrington; Esther Sweeney; Ilyas Alav; Freya Allen; John Moat; Freya Harrison

doi:10.3791/62187

/

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

JoVE Journal
İmmünoloji ve Enfeksiyon

This content is Free Access.

JoVE Journal İmmünoloji ve Enfeksiyon

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

6,324 Views

•

09:26 min

•

January 22, 2021

DOI:

10.3791/62187-v

DOI:

10.3791/62187-v

•

09:26 min

January 22, 2021

•

4 Views

Niamh E. Harrington*¹, Esther Sweeney*¹, Ilyas Alav^1,2, Freya Allen¹, John Moat^1,3, Freya Harrison¹

¹School of Life Science,University of Warwick, ²Institute of Microbiology and Infection,University of Birmingham, ³Warwick Antimicrobial Screening Facility, School of Life Science,University of Warwick

Özet

This workflow can be used to perform antibiotic susceptibility testing using an established ex vivo model of bacterial biofilm in the lungs of individuals with cystic fibrosis. Use of this model could enhance the clinical validity of MBEC (minimal biofilm eradication concentration) assays.

Explore More Videos

Antibiotic Efficacy Pseudomonas Aeruginosa Staphylococcus Aureus Biofilms Cystic Fibrosis Lung Ex Vivo Model Bronchiole DMEM RPMI 1640 Antibiotic Susceptibility Testing

Read Article

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Özet

Automatically generated

Explore More Videos